A young man sent to live in a care home gained 20kg in weight within six months of his admission, and then died.

Family genetics evaluations. Several family visits with the geneticist and subsequent laboratory evaluations revealed that Bobby had PWS. It was also established that his siblings did not have the ...

A Prescription Drug User Fee Act target date of December 27, 2024 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...

Soleno Therapeutics, Inc. (SLNO) is gearing up to file a New Drug Application [NDA] to the FDA of Diazoxide Choline [DCCR] for the treatment of patients with Prader-Willi Syndrome [PWS] in mid-2024.

New research from the University of East Anglia (UK) reveals the hidden struggles experienced by the brothers and sisters of ...

Man with Prader-Willi Syndrome died of multi-organ failure from a complication of undiagnosed diabetes, triggered by ...

Treatment with intranasal carbetocin was not associated with a statistically significant improvement in hyperphagia compared with placebo. Topline results were announced from a phase 3 trial ...

Please see the full Prescribing Information, including Medication Guide.

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients ...

-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with ...

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint Acadia Pharmaceuticals Inc. (Nasdaq ...